|
We asked 40 pharma leaders, Pharma agents and employees should never post messages that promote or mention brand name drugs, whether they remain anonymous or not?
| Strongly agree |
66% |
| Agree |
11% |
| Disagree |
17% |
| Strongly disagree |
6% |
 |
|
|
|
|
|
|
|
24 July, 2012
|
| In this Issue |
Paring the Fat in Clinical Trials
New research from the Tuft's Center for the Study of Drug Development provides answers to some basic strategic questions: what is contributing to the run-up in costs in trial protocols, and where and how can savings be made? Read more... |
Missed Opportunities in Rare Disease
At CBI’s 7th Annual Rare Disease and Orphan Drug Leadership Congress, speakers and attendees identified areas where pharma can improve the way it approaches rare disease and treatment. Ben Comer reports. More... |
"Data is the New Oil": Open Access to Sweep Europe?
After almost simultaneous announcements by the UK government and the European Commission, Europe looks set for a radical shake-up of academic publishing and access to scientific research. More... |
What is 'Big Data' and How Can We Use It?
Why, with all the data available, are pharma companies so bad at getting true marketing insights to drive their business? Bill Drummy asks how marketers can realize the promise of "Big Data". More...
|
Naught UK Localities Need to Obey NICE, Or Else!
Like US state governors vowing to block Medicaid expansion in their home states, local primary care trusts (PCTs) in the UK don’t always follow national guidelines on drug access due to budgetary concerns. But that may change in 2013; according to comments made by Minister David Willetts last month, NHS could face monetary penalties for not making newly approved drugs available to patients fast enough. More...
|
|
|
|
